Filter posts

Big Ventures

It is rare to see triple digit millions in private financing rounds, but it does …

The Good, the Bad, and the Ugly for Biotech IPOs

The troubles in the biotech IPO market are complicated to explain to industry outsiders. They …

Labeling Foes: Fight if You Want, But We’ve Got to Feed the World

There were still millions of votes left to be counted in California when advocates for …

BayBio Op-ed featured in Xconomy

Gail Maderis, President & CEO of BayBio, recently discussed the strength of Northern California’s biotechnology …

BIO Investor Forum: The New Kids on the Biotech Block

Where should biotech start-ups look for funding in the venture capital desert that is becoming …

How does the NBI perform in the last quarter of the year?

Does the NASDAQ Biotech Index (NBI) outperform the broader market in the last three months …

A Start-Up Model Worthy of Consideration

Biotech LLCs are getting a lot of attention lately, and perhaps rightfully so. The Wall …

BioSpectrum Asia Survey Shows Promising Results for the Biosciences Industry

BioSpectrum Asia recently completed a survey of close to 500 bioscience companies listed on different …

Biotech’s Drought-Tolerant Corn Stands Tall

As drought conditions worsen across the midwest, drought-tolerant corn products are being put to the …

Just What the Doctor Ordered: Biotech’s Improved Apple

There’s a lot of buzz right now over the new “Arctic Apple,” genetically engineered to …